Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Myositis
•
Dermatomyositis
How do you approach sequentially tapering combination therapy (ie: IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
Would you taper the IVIG first or the cellcept/rituximab?
Related Questions
How do you go about switching from one DMARD to another In patients with dermatomyositis that remains active?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?
How do you approach weakly positive PL-7 antibody in a patient who initially presented with muscle weakness, rhabdomyolysis and non specific muscular edema on MRI that resolved with IV fluids?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
What is the stepwise investigation of patients suspected of inflammatory myopathy?
Are there situations in which you treat calcinosis cutis that is not symptomatic for the patient?
Is there any role for IVIG or steroids in viral myositis complicated by severe rhabdomyolysis, diffuse compartment syndrome, DIC, and AKI?
How would you approach a young patient with bilateral lower extremity muscle weakness and positive anti-Smith, dsDNA, RNP, Raynaud’s, and pericardial effusion but normal muscle enzymes?